tetano
Editor, Senior Moderator
F1000Res
. 2021 Feb 3;10:64.
doi: 10.12688/f1000research.36396.3. eCollection 2021.
Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis
Shinta Oktya Wardhani[SUP] 1 [/SUP], Jonny Karunia Fajar[SUP] 2 [/SUP], Laksmi Wulandari[SUP] 3 [/SUP], Gatot Soegiarto[SUP] 4 [/SUP], Yeni Purnamasari[SUP] 5 [/SUP], Anisa Asmiragani[SUP] 5 [/SUP], Helnida Anggun Maliga[SUP] 5 [/SUP], Muhammad Ilmawan[SUP] 5 [/SUP], Gloriana Seran[SUP] 6 [/SUP], Dheka Sapti Iskandar[SUP] 7 [/SUP], Conchita Emiliana Ndapa[SUP] 8 [/SUP], Viviana Hamat[SUP] 8 [/SUP], Rafika Ajeng Wahyuni[SUP] 5 [/SUP], Linda Oktaviana Suci Cyntia[SUP] 5 [/SUP], Feronika Maryanti Maarang[SUP] 9 [/SUP], Yosef Andrian Beo[SUP] 9 [/SUP], Olivera Agnes Adar[SUP] 8 [/SUP], Iraky Mardya Rakhmadhan[SUP] 5 [/SUP], Emilia Tiara Shantikaratri[SUP] 5 [/SUP], Ayu Sekarani Damana Putri[SUP] 5 [/SUP], Rizqa Wahdini[SUP] 5 [/SUP], Endang Pati Broto[SUP] 10 [/SUP], Agnes Wanda Suwanto[SUP] 11 [/SUP], Fredo Tamara[SUP] 2 [/SUP], Aditya Indra Mahendra[SUP] 2 [/SUP], Eden Suryoiman Winoto[SUP] 2 [/SUP], Pratista Adi Krisna[SUP] 2 [/SUP], Harapan Harapan[SUP] 12 [/SUP]
Affiliations
Abstract
Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non - RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.
Keywords: COVID-19; convalescent plasma; mortality; outcomes; passive immunization.
. 2021 Feb 3;10:64.
doi: 10.12688/f1000research.36396.3. eCollection 2021.
Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis
Shinta Oktya Wardhani[SUP] 1 [/SUP], Jonny Karunia Fajar[SUP] 2 [/SUP], Laksmi Wulandari[SUP] 3 [/SUP], Gatot Soegiarto[SUP] 4 [/SUP], Yeni Purnamasari[SUP] 5 [/SUP], Anisa Asmiragani[SUP] 5 [/SUP], Helnida Anggun Maliga[SUP] 5 [/SUP], Muhammad Ilmawan[SUP] 5 [/SUP], Gloriana Seran[SUP] 6 [/SUP], Dheka Sapti Iskandar[SUP] 7 [/SUP], Conchita Emiliana Ndapa[SUP] 8 [/SUP], Viviana Hamat[SUP] 8 [/SUP], Rafika Ajeng Wahyuni[SUP] 5 [/SUP], Linda Oktaviana Suci Cyntia[SUP] 5 [/SUP], Feronika Maryanti Maarang[SUP] 9 [/SUP], Yosef Andrian Beo[SUP] 9 [/SUP], Olivera Agnes Adar[SUP] 8 [/SUP], Iraky Mardya Rakhmadhan[SUP] 5 [/SUP], Emilia Tiara Shantikaratri[SUP] 5 [/SUP], Ayu Sekarani Damana Putri[SUP] 5 [/SUP], Rizqa Wahdini[SUP] 5 [/SUP], Endang Pati Broto[SUP] 10 [/SUP], Agnes Wanda Suwanto[SUP] 11 [/SUP], Fredo Tamara[SUP] 2 [/SUP], Aditya Indra Mahendra[SUP] 2 [/SUP], Eden Suryoiman Winoto[SUP] 2 [/SUP], Pratista Adi Krisna[SUP] 2 [/SUP], Harapan Harapan[SUP] 12 [/SUP]
Affiliations
- PMID: 34136130
- PMCID: PMC8182694
- DOI: 10.12688/f1000research.36396.3
Abstract
Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non - RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.
Keywords: COVID-19; convalescent plasma; mortality; outcomes; passive immunization.